Cardiovascular chemotherapy: Anticoagulants

Current Opinion in Chemical Biology

Volumn 2, Issue 4, 1998, Pages 458-465

  Shafer, Jules A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; THROMBIN;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; HUMAN; LUNG EMBOLISM; REVIEW; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANTICOAGULANTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DRUG DESIGN; FACTOR XA; HUMANS; PULMONARY EMBOLISM; THROMBIN; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0032135007     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(98)80121-X     Document Type: Article

References (59)

1. Jesty J: The kinetics of inhibition of α-thrombin in human plasma. J Biol Chem 1986, 261:10313-10318.
2. Rosenberg R: Biochemistry and pharmacology of low molecular weight heparin. Semin Hematol 1997, 34(suppl 4):2-8.
3. Olson ST, Shore JD: Demonstration of a two-step reaction mechanism for inhibition of α-thrombin by antithrombin III and identification of the step affected by heparin. J Biol Chem 1982, 257:14891-14895.
4. Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J: Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992, 267:12528-12538.
5. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE: Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997, 7:361-367.
6. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D et al.: A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993, 329:1370-1376.
7. Clagett GP, Anderson FA Jr, Heit J, Levine MN, Wheeler HB: Prevention of venous thromboembolism. Chest 1995, 108:3128-3348.
8. Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G: Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement N Engl J Med 1996, 335:696-700.
9. 506) as potential risk factors for thrombosis after elective hip arthroplasty. Thromb Haemost 1997, 78:993-996.
10. Planes A, Vochelle N, Darmon J-Y, Fagola M, Bellaud M, Huet Y: Rick of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996, 348:224-228.
11. Dahl OE, Andreassen G, Aspelin T, Müller C, Mathiesen P, Nyhus S, Abdelnoor M, Solhaug J-H, Arnesen H: Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997, 77:26-31.
12. Imperiale TF, Speroff T: A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994, 271:1780-1785. (Published erratum appears in JAMA 1995, 273:288).
13. Hull RD, Raskob GE, Pineo GF, Feldstein W, Rosenbloom D, Gafni A, Green D, Feinglass J, Trowbridge AA, Elliott CG et al.: Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. Arch Intern Med 1997, 157:298-303. This paper presents an in-depth analysis of the costs and effectiveness of low molecular weight heparin and warfarin therapy.
14. Eriksson BI, Wille-Jorgensen P, Kälebo P, Mouret P, Rosencher N, Bosch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P: A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997, 337:1329-1335. This report is the first definitive study wherein the efficacy of hirudin as an anticoagulant for prevention of deep vein thrombosis in man is demonstrated.
15. Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P, Levine MN, Panju AA, Powers P, Stevens P et al.: Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994, 90:2385-2389.
16. Columbus Investigators: Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997, 337:657-662.
17. Holmström M, Lindmarker P, Granqvist S, Johnsson H, Lockner D: A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis. Thromb Haemost 1997, 78:803-807. This study, together with [16,18,19], documents the efficacy of low molecular weight heparin (LMWH) in the treatment of deep vein thrombosis, and the reduction in hospital stays associated with LMWH therapy.
18. Levine, M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M et al.: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996, 334:677-681.
19. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH et al.: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996, 334:682-687.
20. Hull RD, Raskob GE, Pineo GF, Brant RF, the Canadian-American Thrombosis Study Group: The treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin. Clin Appl Thromb - Hemost 1995, 1:151-159.
21. Pini M, Aiello S, Manotti C, Pattacina C, Quintavalla R, Poli T, Tagliaferri A, Dettori AG: Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994, 72:191-197.
22. Eichinger S, Pabinger I, Stümpflen A, Hirschl M, Bialonczyk C, Schneider B, Mannhalter C, Minar E, Lechner K, Kyrie PA: The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997, 77:624-628. This study exemplifies the need for chronic oral anticoagulation therapy, but indicates that patients with factor V Leiden are not at a greater risk for recurrent deep vein thrombosis (DVT). This result may reflect unrecognized risk factors in patients with DVT without factor V Leiden.
23. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund S-G, Nordlander S, Lärfars G, Leijd B et al.: The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997, 336:393-398. This paper documents the need for chronic oral anticoagulant therapy in patients suffering from deep vein thrombosis.
24. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM: Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994, 74:236-241.
25. Howard PA, Duncan PW: Primary stroke prevention in nonvalvular atrial fibrillation: implementing the clinical trial findings. Ann Pharmacother 1997, 31:1187-1196. This review documents the need for warfarin therapy INR 2-3 to prevent stroke in the setting of atrial fibrillation.
26. Hylek EM, Skates SJ, Sheehan MA, Singer DE: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996, 335:540-546.
27. Rosendaal FR: The scylla and charybdis of oral anticoagulant treatment. N Engl J Med 1996, 335:587-589.
28. Coumadin Aspirin Reinfarction Study (CARS) Investigators: Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997, 350:389-396. This study documents that, even in the presence of aspirin, low fixed dose warfarin yields suboptimal protection from thromboembolism.
29. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group: Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994, 343:499-503.
30. Shafer JA: Direct thrombin inhibitors: active-site inhibitors of thrombin. In New Therapeutic Agents in Thrombosis and Thrombolysis. Edited by Sasahara AA, Loscalzo J. New York: Marcel Decker Inc; 1997:143-157.
31. Schwarz Jr RP, Becker J-C P, Brooks, RL, Hursting MJ, Joffrion JL, Knappenberger GD, Kogan TP, Kogan PW, McKinney AA: The preclinical and clinical pharmacology of novastan (argatroban): a small-molecule, direct thrombin inhibitor. Clin Appl Thromb - Hemost 1997, 31:1-15. This detailed description of the pharmacological properties of a thrombin inhibitor, which has been approved in Japan for use in man, provides useful information for benchmarking anticoagulants during preclinical development.
32. Nainggolan L (Ed): Argatroban disappoints in thrombolysis. SCRIP 1998, 2326/27:19.
33. Lyle TA, Chen Z, Appleby SD, Freidinger RM, Gardell SJ, Lewis SD, Li Y, Lyle EA, Lynch Jr JJ, Mulichak AM et al.: Synthesis, evaluation, and crystallographic analysis of L-371,912: a potent and selective active-site thrombin inhibitor. Bioorg Med Chem Lett 1997, 7:67-72. This paper presents an X-ray crystallographic analysis of potency-enhancing effects.
34. Häkansson K, Tulinsky A, Abelman MM, Miller TA, Vlasuk GP, Bergum PW, Lim-Wilby MS, Brunck TK: Crystallographic structure of a peptidyl keto acid inhibitor and human α-thrombin. Bioorg Med Chem 1995, 3:1009-1017.
35. Lewis SD, Lucas BJ, Brady SF, Sisko JT, Cutrona KJ, Sanderson PEJ, Freidinger RM, Mao S-S, Gardell SJ, Shafer JA: Characterization of the two-step pathway for inhibition of thrombin by α-ketoamide transition state analogs. J Biol Chem 1998, 273:4843-4854. This paper provides new methods for dissecting enzyme-inhibitor interactions.
36. Brady SF, Lewis SD, Colton CD, Stauffer KJ, Sisko JT, Ng S, Homnick CF, Bogusky MJ, Shafer JA, Veber DF, Nutt RF: Development of highly potent and selective α-keto carbonyl thrombin inhibitors with novel P1 side chains: synthesis and biological profile of L-370,518. In Peptides, Chemistry, Structure and Biology. Edited by Kaumaya TP, Hodges RS. Kingswinford: Mayflower Scientific Ltd; 1996:331-333.
37. Lewis SD, Ng AS, Lyle EA, Mellott MJ, Appleby SD, Brady SF, Stauffer KJ, Sisko JT, Mao S-S, Veber DF et al.: Inhibition of thrombin by peptides containing lysyl-α-keto carbonyl derivatives. Thromb Haemost 1995, 74:1107-1112.
38. Brady SF, Sisko JT, Stauffer KJ, Colton CD, Qiu H, Lewis SD, Ng AS, Shafer JA, Bogusky MJ, Veber DF, Nutt RF: Amide and α-keto carbonyl inhibitors of thrombin based on arginine and lysine: synthesis, stability and biological characterization. Bioorg Med Chem 1995, 3:1063-1078.
39. Weber PC, Lee S-L, Lewandowski FA, Schadt MC, Chang C-H, Kettner CA: Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine and orthithine analogs. Biochemistry 1995, 34:3750-3757.
40. Lee S-L, Alexander RS, Smallwood A, Trievel R, Mersinger L, Weber PC, Kettner C: New inhibitors of thrombin and other trypsin-like proteases: hydrogen bonding of an aromatic cyano group with a backbone amide of the P1 binding site replaces binding of a basic side chain. Biochemistry 1997, 36:13180-13186. This paper describes an interesting approach for enhancing the potency of thrombin inhibitors with a neutral P1 group.
41. Richard BM, Nolan TG, Tran HS, Miller MM, Nutt RF, Vlasuk GP: Bioavailability of a novel, direct thrombin inhibitor in non-human primates following oral administration. Circulation 1994, 90:1-18.
42. Tucker TJ, Lumma WC, Mulichak AM, Chen Z, Naylor-Olsen AM, Lewis SD, Lucas R, Freidinger RM, Kuo LC: Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site. J Med Chem 1997, 40:830-832. This paper exemplifies the application of structure/activity studies to identify unusually potent inhibitors.
43. Tucker TJ, Lumma WC, Lewis SD, Gardell SJ, Lucas BJ, Baskin EP, Weltmann R, Lynch JJ, Lyle EA, Appleby SD et al.: Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy. J Med Chem 1997, 40:1565-1569.
44. Tucker TJ, Lumma WC, Lewis SD, Gardell SJ, Lucas BJ, Sisko JT, Lynch JJ, Lyle EA, Baskin EP, Weltmann RF et al.: Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position. J Med Chem 1997, 40:3687-3693. This paper exemplifies optimization of lipophilicity to achieve oral bioavailability and in vivo anticoagulant potency.
45. Brady SF, Stauffer KJ, Lumma WC, Smith GM, Ramjit HG, Lewis SD, Lucas BJ, Gardell SJ, Lyle EA, Appleby SD et al.: Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support. J Med Chem 1998, 41:401-406.
46. Feng D-M, Gardell SJ, Lewis SD, Bock MG, Chen Z, Freidinger RM, Naylor-Olsen AM, Ramjit HG, Woltmann R, Baskin EP et al.: Discovery of a novel, selective and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position. J Med Chem 1997, 40:3726-3733.
47. Sanderson PEJ, Cutrona KJ, Dorsey BD, Dyer DL, McDonough CM, Naylor-Olsen AM, Chen I-W, Chen Z, Cook JJ, Gardell SJ et al.: L-374,087, an efficacious orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorg Med Chem Letts 1998, 8:817-822. This paper illustrates how alteration of the basicity of a thrombin inhibitor can increase oral bioavailability.
48. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Pehrsson S et al.: Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998, 79:110-118.
49. Elg M, Gustafsson D, Deinum J: The importance of enzyme inhibition kinetics for thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997, 78:1286-1292.
50. Oh YS, Yun M, Hwang SY, Hong S, Shin Y, Lee K, Yoon KH, Yoo YJ, Kim DS, Lee SH et al.: Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor. Bioorg Med Chem Lett 1998, 8:631-634.
51. Allen M, Abel SM, Barber CG, Cussans NJ, Danielewicz JC, Ellis D, Hawkeswood E, Herron M, Holland S, Fox DNA et al.: The discovery of UK-156,406-an orally active thrombin inhibitor. Book of abstracts. 215th American Chemical Society National Meeting, Dallas, March 29-April 2 1998; Washington, DC: American Chemical Society; 1998:A200.
52. Stürzebecher J, Prasa D, Hauptmann J, Vieweg H, Wikström P: Synthesis and structure - activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine. J Med Chem 1997, 40:3091-3099.
53. Chirgadze NY, Sall DJ, Klimkowski VJ, Clawson DK, Briggs SL, Herman R, Smith GF, Gifford-Moore DS, Wery J-P: The crystal structure of human α-thrombin complexed with LY178550, a nonpeptidyl, active site-directed inhibitor. Protein Sci 1997, 6:1412-1417. This paper characterizes the interactions of thrombin with a new class of amidinoindole nonpeptidyl thrombin inhibitors.
54. Sail DJ, Bastian JA, Briggs SL, Buben JA, Chirgadze NY, lawson DK, Denney ML, Giera DD, Gifford-Moore DS, Harper RW et al.: Dibasic benzo[b]thiophene derivatives as a novel class of active site-directed thrombin inhibitors. 1. Determination of the serine protease selectivity, structure-activity relationships, and binding orientation. J Med Chem 1997, 40:3489-3493. This paper characterizes the interactions of thrombin with a novel class of dibasic benzothiophene nonpeptidyl inhibitors.
55. Sail DJ, Bastian JA, Chirgadze NY, Denney ML, Gifford-Moore DS, Harper TRW, Kohn TJ, Lin H-S, McCowan JR, Richett ME et al.: Dibasic benzo(b)thiophene derivatives as a novel class of thrombin inhibitors. 3. Optimization of the C-3 sidechain. Book of abstracts. 214th American Chemical Society National Meeting, Las Vegas, September 7-11 1997; Washington, DC: American Chemical Society; 1998:A57.
56. Obst U, Banner DW, Weber L, Diederich F: Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes. Chem Biol 1997, 4:287-295. Rigid bicyclic and tricyclic nonpeptidyl thrombin inhibitors are characterized in this study.
57. Wiley MR, Fisher MJ: Small-molecule direct thrombin inhibitors. Exp Opin Ther Patents 1997, 7:1265-1282.
58. Al-Obeidi F, Ostrem JA: Factor Xa inhibitors by classical and combinatorial chemistry. Drug Discov Today 1998, 3:223-231.
59. Brandstetter H, Kühne A, Bode W, Hubert R, von der Saal W, Wirthensohn K, Engh RA: X-ray structure of active site-inhibited clotting factor Xa. J Biol Chem 1996, 271:29988-29992.